Bristol-Myers Squibb (BMY) FY2016 results: revenue $19.4 billion, up 17.3% on the year
Bristol-Myers Squibb Co. (BMY) reported revenue of $19.4 billion for fiscal 2016, the year ended 31 December 2016, up 17.3% on the year before. Net income was $4.5 billion, up 184.8%, and diluted earnings per share $2.65. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2019.
Revenue
$19.4 billion
+17.3% on the year
FY2009FY2016
Operating margin
30.4%
12.5% a year earlier
FY2009FY2016
Net income
$4.5 billion
+184.8% on the year
FY2009FY2016
Diluted EPS
$2.65
+184.9% on the year
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
19,427
16,560
15,879
+17.3%
Cost of revenue
4,969
3,909
3,932
+27.1%
Gross profit
14,481
12,651
11,947
+14.5%
Gross margin
74.5%
76.4%
75.2%
Research and development
5,012
5,920
4,534
-15.3%
Selling, general and administrative
4,979
4,841
4,822
+2.9%
Operating income
5,915
2,077
2,381
+184.8%
Operating margin
30.4%
12.5%
15.0%
Interest expense
167
184
203
-9.2%
Pre-tax income
5,915
2,077
2,381
+184.8%
Income tax
1,408
446
352
+215.7%
Effective tax rate
23.8%
21.5%
14.8%
Net income
4,457
1,565
2,004
+184.8%
Net margin
22.9%
9.5%
12.6%
Diluted EPS
$2.65
$0.93
$1.20
+184.9%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
3,058
2,105
3,148
+45.3%
Capital expenditure
1,215
820
526
+48.2%
Free cash flow
1,843
1,285
2,622
+43.4%
Free cash flow margin
9.5%
7.8%
16.5%
Cash from investing
1,480
-1,572
1,216
Cash from financing
-2,653
-3,624
-2,437
Depreciation and amortisation
382
376
467
+1.6%
Share-based compensation
205
235
213
-12.8%
Buybacks
231
n/a
n/a
Dividends paid
2,547
2,477
2,398
+2.8%
Dividend per share
$1.53
$1.49
$1.45
+2.7%
Diluted shares, weighted
1,680m
1,679m
1,670m
+0.1%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
16,177
14,266
14,852
+13.4%
Non-controlling interest
170
158
131
+7.6%
Debt
6,708
6,689
7,832
+0.3%
Other liabilities
10,652
10,635
10,934
+0.2%
Total liabilities and equity
33,707
31,748
33,749
+6.2%
Fixed assets
4,980
4,412
4,417
+12.9%
Goodwill
6,875
6,881
7,027
-0.1%
Intangible assets
1,385
1,419
1,753
-2.4%
Investments
4,832
6,545
6,272
-26.2%
Cash and equivalents
4,237
2,385
5,571
+77.7%
Receivables
3,774
2,948
2,100
+28.0%
Inventory
1,241
1,221
1,560
+1.6%
Other assets
6,383
5,937
5,049
+7.5%
Total assets
33,707
31,748
33,749
+6.2%
10-K for the year ended 31 December 2016, filed 25 February 2019: the filing.